Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene

Lung Cancer

Volumn 77, Issue 3, 2012, Pages 507-514

  Pelosi, Giuseppe ^a,b   Gasparini, Patrizia ^a   Cavazza, Alberto ^c   Rossi, Giulio ^d   Graziano, Paolo ^e   Barbareschi, Mattia ^f   Perrone, Federica ^a   Barberis, Massimo ^g   Takagi, Masayuki ^h   Kunimura, Toshiaki ⁱ   Yamada, Tetsuya ^j   Nakatani, Yukio ^k   Pastorino, Ugo ^a   Scanagatta, Paolo ^a   Sozzi, Gabriella ^a   Garassino, Marina ^a   De Braud, Filippo ^a   Papotti, Mauro ^l  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Arcispedale S Maria Nuova   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f SANTA CHIARA HOSPITAL   (Italy)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^j Gifu Municipal Hospital   (Japan)

^k CHIBA UNIVERSITY HOSPITAL   (Japan)

^l UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

ALK; Amplification; Biopsy; Diagnosis; Lung; Mutation; Sarcomatoid carcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; CARCINOSARCOMA; CENTROMERE; CHROMOSOME 17; CHROMOSOME 2; CHROMOSOME 7; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG BIOPSY; LUNG BLASTOMA; LUNG CARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; MALE; METASTASIS; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; SARCOMATOID CARCINOMA; SEQUENCE ANALYSIS; SPINDLE CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84865178051     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.05.093     Document Type: Article

References (44)

1. Kaira K., Horie Y., Ayabe E., Murakami H., Takahashi T., Tsuya A., et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010, 5:460-465.
2. Aketa A., Yamada G., Aketa K., Ohnishi T., Takahashi Y., Kudoh K., et al. Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma. Nihon Kokyuki Gakkai Zasshi 2004, 42:164-169.
3. Bae H.M., Min H.S., Lee S.H., Kim D.W., Chung D.H., Lee J.S., et al. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer 2007, 58:112-115.
4. Nakamura S., Horiuchi N., Katsura D., Shichijo K., Yoshida S., Harada E., et al. A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy. Gan To Kagaku Ryoho 2008, 35:965-968.
5. Pelosi G., Sonzogni A., De Pas T., Galetta D., Veronesi G., Spaggiari L., et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010, 18:103-120.
6. Travis W., Brambilla E., Muller-Hermelink H., Harris C. Tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
7. Ichihara S., Toyooka S., Fujiwara Y., Hotta K., Shigematsu H., Tokumo M., et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 2007, 120:1239-1247.
8. Saitoh M., Niijima M., Takiguchi Y., Hiroshima K., Fujita Y., Nishio K., et al. An early event of EGFR mutation in pleomorphic carcinoma of the lung. Int J Clin Oncol 2011.
9. Sugio K., Uramoto H., Ono K., Oyama T., Hanagiri T., Sugaya M., et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006, 94:896-903.
10. Ushiki A., Koizumi T., Kobayashi N., Kanda S., Yasuo M., Yamamoto H., et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol 2009, 39:267-270.
11. Chang Y.L., Wu C.T., Shih J.Y., Lee Y.C. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Ann Surg Oncol 2011.
12. Pelosi G., Scarpa A., Manzotti M., Veronesi G., Spaggiari L., Fraggetta F., et al. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004, 17:538-546.
13. Italiano A., Cortot A.B., Ilie M., Martel-Planche G., Fabas T., Pop D., et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009, 125:2479-2482.
14. Macher-Goeppinger S., Penzel R., Roth W., Dienemann H., Thomas M., Schnabel P.A., et al. Expression and mutation analysis of EGFR, c-KIT, and beta-catenin in pulmonary blastoma. J Clin Pathol 2011, 64:349-353.
15. Holst V., Finkelstein S., Colby T., Myers J., Yousem S. p53 an K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis. Am J Surg Pathol 1997, 21:801-811.
16. Przygodzki R., Koss M., Moran C., Langer J., Swalsky P., Fishback N., et al. Pleomorphic (giant an spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis. Am J Clin Pathol 1996, 106:487-492.
17. Leone A., Graziano P., Gasbarra R., Paone G., Cardillo G., Mancuso A., et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer 2010.
18. Watanabe K., Ishida T., Fukuhara A., Sekine S., Uekita K., Sugawara A., et al. A case of pulmonary pleomorphic carcinoma with epidermal growth factor receptor (EGFR) mutation. Gan To Kagaku Ryoho 2008, 35:1595-1597.
19. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
20. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837.
21. Takahashi K., Kohno T., Matsumoto S., Nakanishi Y., Arai Y., Fujiwara T., et al. Clonality and heterogeneity of pulmonary blastoma from the viewpoint of genetic alterations: a case report. Lung Cancer 2007, 57:103-108.
22. Lee S., Kim Y., Sun J.M., Choi Y.L., Kim J.G., Shim Y.M., et al. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 2011, 137:1203-1211.
23. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005, 65:9455-9462.
24. Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002, 297:63-64.
25. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12:175-180.
26. Salido M., Pijuan L., Martinez-Aviles L., Galvan A.B., Canadas I., Rovira A., et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011, 6:21-27.
27. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-655.
28. Liu L., Shao X., Gao W., Bai J., Wang R., Huang P., et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010, 5:1922-1932.
29. Pelosi G., Del Curto B., Dell'Orto P., Pasini F., Veronesi G., Spaggiari L., et al. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer 2005, 113:101-108.
30. Pelosi G., Fabbri A., Bianchi F., Maisonneuve P., Rossi G., Barbareschi M., et al. Δ(Delta)Np63 (p40) and thyroid transcription factor-1 (TTF1) immunoreactivity upon small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012, 7:281-290.
31. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
32. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
33. Perner S., Wagner P.L., Demichelis F., Mehra R., Lafargue C.J., Moss B.J., et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008, 10:298-302.
34. Kendall J., Liu Q., Bakleh A., Krasnitz A., Nguyen K.C., Lakshmi B., et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A 2007, 104:16663-16668.
35. Yatabe Y., Matsuo K., Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011, 29:2972-2977.
36. Chiosea S.I., Sherer C.K., Jelic T., Dacic S. KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol 2011.
37. Pelosi G., Gasparini P., Sozzi G., Caserini R., Cavazza A., Rossi G., et al. Fluorescence in situ hybridization (FISH)-assessed amplification of anaplastic lymphoma kinase (ALK) gene is detecable in a subset of pulmonary sarcomatoid carcinomas (PSC). Mod Pathol 2012, 25(Suppl. 2):486A. (abstract # 2027).
38. van Essen H.F., Ylstra B. High-resolution copy number profiling by array CGH using DNA isolated from formalin-fixed, paraffin-embedded tissues. Methods Mol Biol 2012, 838:329-341.
39. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
40. Camidge D.R., Theodoro M., Maxson D.A., Skokan M., O'Brien T., Lu X., et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012, (January). [Epub ahead of print]. 10.1002/cncr.27411.
41. Pelosi G., Sonzogni A., Viale G. The classification of lung carcinoma: time to change the morphology-based approach?. Int J Surg Pathol 2010, 18:161-172.
42. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009, 22:508-515.
43. Nakatani Y., Miyagi Y., Takemura T., Oka T., Yokoi T., Takagi M., et al. Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol 2004, 28:921-927.
44. Yao H., Ashihara E., Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin Ther Targets 2011, 15:873-887.